To view this content, you need to sign in.
You should only be asked to sign in once. Not the case? Click here
Register now to access this content and more for free.
VC-backed Aligos Therapeutics goes public
Aligos Therapeutics, a biopharmaceutical company focused on treating viral infections and liver diseases, has raised about $150 million for its IPO after pricing its 10 million shares at $15 per share.
